بحث بيانات أعضاء هيئة التدريس - جامعة الزقازيق

/ بحث بيانات أعضاء هيئة التدريس - جامعة الزقازيق

عمرو شعبان حنفى السيد

الموقع الشخصى

عمرو شعبان حنفى السيد

الكلية الطب - القسم الباطنة العامة
الباطنه العامه

الدرجات العلمية

بكالوريوس فى الطب والجراحه, -جامعة الزقازيق [2000]
ماجستير فى الباطنه العامه, -جامعة الزقازيق [2006]
(لتنبؤ اللاختراقى لدوالى المرئ فى مرضى التليف الكبدى المتكافئ)
دكتوراه فى الباطنه العامه, -جامعة الزقازيق [2011]
(مستوى البروتين المرتبط بالريتينول ـ4 فى مرضىالفيروس الكبدى سى المزمن)

الحالة الوظيفية الحالية :

قائم بالعمل

التدرج الوظيفى الأكاديمى

معيد : 3/3/2005
مدرس مساعد : 15/3/2006
مدرس : 23/8/2011
أستاذ مساعد : 30/8/2016
أستاذ : 28/9/2021

الأبحاث العلمية

1 - Efficacy of baseline Serum 25 OH Vitamin D during enhanced Systemic inflammation in predicting response to antiviral therapy for Egyptian Patients with HCV. (1435).

2 - Prevalence of HCV infection among Patients with Inflammatory Polyarthritis Resistant to Conventional Therapy. (1436).

3 - Association of thrombogenic gene polymorphisms with hepatocellular carcinoma in HCV Egyptian patients (1437).

4 - Efficacy of a novel risk score in prediction of systemic hypertension in young male patients; the role of laboratory biomarkers in primary prevention. (1437).

5 - The role of ascitic fluid viscosity in differentiating the nature of ascites, prediction of renal impairment and duration of ICU stay (1437).

6 - Adding rifaximin and midodrine enhances diuresis in refractory or recurrent ascites with improvement in clinical outcome including renal function, weight loss and short term survival. (1437).

7 - Impact of Helicobacter Pylori eradication on refractory thrombocytopenia in patients with chronic HCV awaiting antiviral therapy. (1437).

8 - Efficacy of low dose capecitabine and sorafenib in patients with advanced alfa-fetoprotein secreting hepatocellular carcinoma: a one year experience. (1437).

9 - efficacy of argon plasma coagulation in the management of portal hypertensive gastropathy (1437).

10 - Association of thrombogenic genes polymorphisms with hepatocellular carcinoma in HCV Egyptian patients. Gene 2016;580: 37–40 (1437).

11 - The relationship between expression of Toll-like Receptor 4 in chronic hepatitis C patients and different stages of liver fibrosis (1439).

12 - Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients (1439).

13 - Impact of hepatitis B vaccination on HBsAg kinetics, interferon-inducible protein 10 level and recurrence of viremia (1438).

14 - Management of different types of gastric varices with band ligation: a 3-year experience (1438).

15 - Pilot study of orphenadrine as a novel treatment for muscle cramps in patients with liver cirrhosis (1438).

16 - A novel scoring system for prediction of esophageal varices in critically ill patients (1439).

17 - Randomized Controlled Study Comparing Use of Propofol Plus Fentanyl versus Midazolam Plus Fentanyl as Sedation in Diagnostic Endoscopy in Patients with Advanced Liver Disease (1439).

18 - Persistence of hepatitis C virus core antigenemia after sustained virological response is associated with worsening of liver function and increased risk of hepatocellular carcinoma (1438).

19 - The utility of difusion‑weighted imaging in improving the sensitivity of LI‑RADS classifcation of small hepatic observations suspected of malignancy (1440).

20 - Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis (1440).

21 - Randomized trial of preoperative administration of oral pregabalin for postoperative analgesia in patients scheduled for radiofrequency ablation of focal lesions in the liver (1439).

22 - Beneficial Effects of Vitamin D on Insulin Sensitivity, Blood Pressure, Abdominal Subcutaneous Fat Thickness, and Weight Loss in Refractory Obesity (1439).

23 - Rescue therapy for chronic hepatitis C virus infection after repeated treatment failures: Impact on disease progression and risk of hepatocellular carcinoma (1440).

24 - Endoscopic management of refractory gastroesophageal reflux disease (1439).

25 - Multifocal fatty liver disease, insulin resistance and carotid atherosclerosis: exploring the interrelated relationship (1440).

26 - A Simple Noninvasive Score Predicts Disease Activity and Deep Remission in Ulcerative Colitis (1439).

27 - Management of HCV‑related decompensated cirrhosis with direct‑acting antiviral agents: who should be treated? (1440).

28 - Refractory Helicobacter pylori gastritis: The hidden predictors of resistance (1440).

29 - Efficacy of a non-invasive model in predicting the cardiovascular morbidity and histological severity in non-alcoholic fatty liver disease (1440).

30 - Residual hepatitis C virus in peripheral blood mononuclear cell as a risk factor for hepatocellular carcinoma after achieving a sustained virological response: a dogma or fiction (1440).

31 - Challenges in COVID-19 drug treatment in patients with advanced liver diseases: A hepatology perspective (1442).

32 - Ascitic Calprotectin as an early predictor of hepatocellular carcinoma in patients with cirrhotic ascites (1442).

33 - Novel markers of endothelial dysfunction in hepatitis C virus-related cirrhosis: More than a mere prediction of esophageal varices (1442).

34 - Prediction and Prevention of Post-hepatectomy Liver Failure: Where Do We Stand? (1442).

35 - Impact of gut Microbiome alteration in Ulcerative Colitis patients on disease severity and outcome (1444).

36 - Potential impact of combined infuenza and pneumococcal vaccines on the severity of respiratory illness in COVID‑19 infection among type 2 diabetic patients (1443).

37 - Real-Life Experience in the Efficacy and Safety of COVID-19 Vaccination in Patients with Advanced Cirrhosis (1445).

38 - Carvedilol to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by novel non-invasive model: an international multicenter study (1444).

39 - A Novel SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102): An International Multicenter Cohort Study (1443).

40 - Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306) (1446).

41 - Prognostic impact of age on outcomes of hepatic decompensation in patients with compensated cirrhosis (CHESS2102): an international, multicenter cohort study (1446).

المجالات البحثية